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Epidemiologic studies demonstrate that obesity is associated with an aggressive subtype
of breast cancer called basal-like breast cancer (BBC). Using the C3(1)-TAg murine model
of BBC, we previously demonstrated that mice displayed an early onset of tumors when
fed obesogenic diets in the adult window of susceptibility. Obesity was also shown to ele-
vate mammary gland expression and activation of hepatocyte growth factor (HGF)/c-Met
compared to lean controls, a pro-tumorigenic pathway associated with BBC in patients.
Epidemiologic studies estimate that weight loss could prevent a large proportion of BBC.
We sought to investigate whether weight loss in adulthood prior to tumor onset would
protect mice from accelerated tumorigenesis observed in obese mice. Using a life-long
model of obesity, C3(1)-TAg mice were weaned onto and maintained on an obesogenic
high-fat diet. Obese mice displayed significant elevations in tumor progression, but not
latency or burden. Tumor progression was significantly reversed when obese mice were
induced to lose weight by switching to a control low-fat diet prior to tumor onset compared
to mice maintained on obesogenic diet. We investigated the HGF/c-Met pathway known
to regulate tumorigenesis. Importantly, HGF/c-Met expression in normal mammary glands
and c-Met in tumors was elevated with obesity and was significantly reversed with weight
loss. Changes in tumor growth could not be explained by measures of HGF action includ-
ing phospho-AKT or phospho-S6. Other mediators associated with oncogenesis such as
hyperinsulinemia and a high leptin:adiponectin ratio were elevated by obesity and reduced
with weight loss. In sum, weight loss significantly blunted the obesity-responsive pro-
tumorigenic HGF/c-Met pathway and improved several metabolic risk factors associated
with BBC, which together may have contributed to the dramatic reversal of obesity-driven
tumor progression. Future research aims to evaluate the role of obesity and the HGF/c-Met
pathway in basal-like breast cancer progression.
Keywords: triple-negative, BMI, high-fat diet, microenvironment, obese, leptin, adiponectin, genetically engineered
mouse model
INTRODUCTION
Epidemiologic and other population studies suggest that obesity
is a risk factor for basal-like breast cancer (BBC) – an aggressive
triple-negative subtype that disproportionately affects young and
African American women (1–8). Studies in various pre-clinical
models of luminal sub-type breast cancers have shown that diet-
induced obesity is associated with shortened mammary tumor
latency (9–11), but little work has been completed on the basal-
like subtype. Thus, we used a unique genetically engineered mouse
model (GEMM) of BBC that most resembles human BBC (12),
the C3(1)-TAg mouse model (13). We have previously demon-
strated that adult-onset obesity reduced BBC latency compared
to lean mice (14). Hepatocyte growth factor (HGF)/c-Met is a
tumor promoting pathway that is significantly activated in BBC
patient samples (15). In C3(1)-TAg mice, obesity increased HGF
and its cognate receptor c-Met expression in the normal mammary
gland and elevated c-Met expression and activation in tumors (14).
Furthermore, our previous work has shown that BBC displays a
significant relationship with stroma-secreted HGF (also known
as scatter factor), a growth factor associated with tumor aggres-
siveness. We reported that when primary fibroblasts were isolated
from mammary glands or tumors of obese mice, these fibrob-
lasts secreted higher concentrations of HGF ex vivo compared to
fibroblasts isolated from lean mice (14). Work from our group (15,
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16) and others (17–19) reported that in humans, the HGF/c-Met
signaling pathway was uniquely regulated by BBC-derived stromal
cells. Interestingly, HGF is elevated in plasma of obese patients and
is reduced with weight loss (20). Taken together, the HGF/c-Met
pathway is one potential mechanism that is associated with obesity
in mice and humans, as well as BBC samples.
Basal-like breast cancer currently has no targeted therapies (21);
hence identification of modifiable risk factors would be therapeu-
tically transformative, especially in reducing disparities associated
with BBC-related mortality. Millikan et al. estimate that approx-
imately half of BBC is attributable to obesity (4), suggesting that
this subtype may be preventable through lifestyle intervention.
However, it is unclear whether prevention of adiposity is needed,or
whether weight loss after obesity could also be effective in reducing
risk. Obesity is an epidemic in the US and worldwide (22, 23) and
is one of the few important modifiable risk factors for breast cancer
(24). Data on the effect of weight loss on BBC risk are limited (25–
27). Hence, the intention of this study was to elucidate the effect
of weight loss on BBC and the molecular mechanisms thereof.
Herein, we assessed if weight reduction through dietary interven-
tion would reverse obesity-induced BBC, and examine important
metabolic parameters and the HGF/c-Met pathway. We report
that when obese C3(1)-TAg mice were induced to lose weight,
the diet switch group (60→ 10%) displayed significantly reduced
tumor progression compared to obese mice. In addition, weight
loss reversed obesity-induced HGF/c-Met expression in normal
mammary gland compared to mice that remained obese. Weight
loss also reduced parameters associated with metabolic syndrome
including hyperinsulinemia and the leptin:adiponectin ratio. Our
findings suggest that obesity-driven factors such as HGF/c-Met,
insulin, and the leptin:adiponectin ratio may contribute to the
onset of obesity-promoted BBCs, and that weight loss prior to
tumor onset may prevent tumor progression.
MATERIALS AND METHODS
REAGENTS AND ANTIBODIES
Anti-mouse HGF antibody that detects total HGF (both pro and
cleaved) and anti-mouse c-Met antibody that detects pro- and
cleaved c-Met were obtained from R&D Systems (Minneapolis,
MN, USA) (14). Adiponectin mouse ELISA kit was obtained
from Abcam (ab108785; Cambridge, MA, USA). Anti-mouse pS6
(Ser235/236) (Cell Signaling 4857) and pAkt (Ser473) (Cell Sig-
naling 3787) was obtained from Cell Signaling Technology, Inc.
(Danvers, MA, USA).
C3(1)-TAG MOUSE MODEL
Animals and diets
Animal studies were performed with approval and in accordance
with the guidelines of the Institutional Animal Care and Use Com-
mittee at the University of North Carolina at Chapel Hill. Female
C3(1)-TAg mice were obtained in collaboration with the UNC
Lineberger Comprehensive Cancer Center (LCCC) Mouse Phase
I Unit (MP1U). C3(1)-Tag mice (13) were used to study the role
of diet on BBC, as these mice were shown to be highly repre-
sentative of human basal-like tumors (12). In females, the simian
virus (SV40) large tumor antigen (Tag) is expressed in the dis-
tal mammary ductal epithelium and terminal ductal lobular unit
in a hormone-independent manner leading to the development
of mammary tumors in female mice (13). C3(1)-Tag mice were
generated by crossing heterozygous male mice with FVB/N non-
transgenic female mice. Diets obtained from Research Diets Inc.
(New Brunswick, NJ, USA) were matched for protein, vitamins,
and minerals, and provided 10% kcal (“10%”); and 60% kcal
(“60%”) derived from fat. Details of the diet components are pro-
vided in Sundaram et al. (14). Female C3(1)-TAg weanlings were
randomly assigned to various diet groups at weaning (3 weeks of
age; n= 15 on 10% and n= 30 on 60%). At 10 weeks of age, half
of the mice on 60% diet were switched to 10% diet (60→ 10%)
(See model of study design, Figure 1).
Body weight and composition
Body weight was measured prior to starting mice on diet and
weekly until sacrifice. Body composition including lean mass,
fat mass, free water content, and total water content of non-
anesthetized mice was also measured at 0, 10, 12, and 14 weeks,
and at sacrifice on diet using the EchoMRI-100 quantitative mag-
netic resonance whole body composition analyzer (Echo Medical
= MRI me points
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FIGURE 1 | Model of study design. Female C3(1)-TAg mice were weaned
onto control low-fat 10% kcal derived from fat (“10%”) or obesogenic 60%
kcal derived from fat (“60%”) diets at 3 weeks of age. At 10 weeks of age,
half of the mice on the 60% diet were switched onto the control 10% diets.
Various endpoints were measured until sacrifice at 3 weeks past tumor
detection.
Frontiers in Oncology | Molecular and Cellular Oncology July 2014 | Volume 4 | Article 175 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sundaram et al. Weight loss inhibits obesity-driven BBC
Systems, Houston, TX, USA). Obesity is defined as greater than a
5% incremental increase in fat composition. Fat mass is presented
as percent fat mass over total body weight (14).
Tumor latency, number, progression (change in volume), and cell
size
As described in Sundaram et al. (14) mice were monitored for
tumor development by palpating three times weekly and tumor
latency was defined as age at detection of first tumor. After detec-
tion of the first tumor, tumor volumes were measured weekly over
3 weeks using calipers to measure the width (short diameter) and
length (long diameter) in millimeter for each tumor. The tumor
volumes were calculated using the formula: length×width2×0.5.
The percent change in volume over time (tumor progression),
was calculated: (End volume – Start volume)/Start volume× 100.
Tumor progression (percent change in volume) of only the first
palpated tumor is presented. Percent change for n= 15 mice was
averaged in each diet group. The total number of tumors per
mouse was counted at sacrifice. Tumor cell diameter was mea-
sured using Aperio ScanScope Image Analysis Toolbox software.
The longest diameters (cytoplasmic membrane; micrometer) of 30
cells from five different fields/tumor section (n= 150 cells) were
averaged to find the overall tumor cell diameter for each sample.
Tissue harvest
Three weeks after detection of the first tumor, mice were anes-
thetized by an intraperitoneal (i.p.) injection of avertin (Fisher
Scientific, Pittsburgh, PA, USA). Blood was collected by cardiac
puncture into a tube with 10µl of 0.05 mM EDTA (final conc).
Plasma was separated by centrifuging blood at 500× g for 5 min.
Plasma was stored at −80°C. Mammary glands without palpable
or visible tumors were collected as “normal,” although atypia of
ductal epithelium could be present in C3(1)-TAg mice (13). Por-
tions of the tissues were placed into a cassette and formalin fixed
for immunohistochemical (IHC) analysis.
Measurement of metabolic parameters and plasma cytokines
Blood glucose, following a 6 h fast, was measured prior to start
of diet, at diet switch, and at sacrifice following a 6 h fast using
a Bayer Contour Blood Glucose Monitor (Bayer HealthCare LLC,
Tarrytown, NY, USA). Metabolically relevant hormones includ-
ing leptin, insulin, IL-6, MCP-1, and TNF-α were measured in
the plasma collected at sacrifice using the Milliplex MAP Mouse
Metabolic Hormone Magnetic Bead Panel in the Luminex MAG-
PIX system (EMD Millipore, Billerica, MA, USA). The homeostasis
model assessment was used to calculate the approximate insulin
resistance (HOMAIR) using the formula (blood glucose (mg/dl at
sacrifice)× plasma insulin levels (at sacrifice)/405) as previously
described (14, 28). Adiponectin concentrations in plasma collected
at sacrifice were measured using the adiponectin mouse ELISA kit
(ab108785; Abcam, Cambridge, MA, USA) following the man-
ufacturer’s protocol. The leptin:adiponectin ratio was calculated
using the measures obtained from the Luminex cytokine panel and
adiponectin ELISA.
Immunohistochemical analyses in normal mammary glands and
tumors
Immunohistochemical analysis was performed for HGF and c-
Met and its downstream signals including pAkt, and pS6 following
the protocol previously described in Sundaram et al. (14). Anti-
mouse HGF antibody and anti-mouse c-Met antibody were used
at a dilution of 1:400 with secondary donkey anti-goat antibody
(1:500; Jackson Immunoresearch; # 705-065-147). Anti-mouse
pS6 and pAkt antibodies were used at a dilution of 1:400 with
secondary goat anti-rabbit antibody (1:500; Jackson Immunore-
search; # 111-005-003). Following staining, slides were scanned
into the Aperio Scanscope CS system (Aperio Technologies, Vista,
CA, USA) at a magnification of 20× and staining was quantified
using the Aperio Imagescope software. The scanned slides were
analyzed using the appropriate algorithms as described previously
(14, 29, 30). The Aperio Imagescope software positive pixel counts
for diaminobenzidine (DAB) staining in the color deconvolution
algorithm was completed for HGF, pAKT, and pS6, and membrane
IHC algorithm for c-Met quantification (14, 29, 30). Aperio digi-
tal analysis of DAB allows for no subjective bias in quantification.
Due to our interest in the normal and tumor microenvironment,
IHC (rather than Western immunoblots of total tissue lysates)
and representative 40× images are presented. An n= 5 random
areas from sections (n= 2 per mouse) were quantified and aver-
aged per animal (n= 8 mice per diet exposure group for HGF
and n= 5 for c-Met, pAKT, and pS6 for both normal mam-
mary glands and tumors). Photomicrographs were obtained at
a magnification of 40×.
STATISTICAL ANALYSIS
Data are expressed as mean± standard error of the mean (SEM).
All means were compared by one way analysis of variance
(ANOVA) with Tukey’s post hoc test for statistical differences in
SPSS (version 20) software (IBM SPSS Statistic 20.0, Armonk, NY,
USA) or GraphPad Prism 5 software (GraphPad Software, Inc.
La Jolla, CA, USA). Kaplan–Meier analyses were conducted using
GraphPad Prism 5 software to estimate tumor latency. Log rank
and chi-square tests were used to investigate differences among
groups. P values<0.05 were considered statistically significant.
RESULTS
OBESITY-INDUCED FROMWEANING CAN BE REVERSED BY
SWITCHING TO A LOW-FAT DIET
Upon weaning at 3 weeks of age, mice were fed control low-fat
10% (n= 15) or obesogenic 60% diets (n= 30). At 10 weeks of
age, n= 15 mice on the obesogenic diet were induced to lose
weight with a diet switch to 10% diet (Figure 1). Mice fed the 60%
diet gained more weight than the control 10%-fed mice, and were
significantly different starting at 9 weeks of age (P = 0.001) and
remained significantly different until end of the study (Figure 2A).
At week 11 (1 week post diet switch), mice on 60→ 10% diets
exhibited weight loss and weights were identical to 10%-fed mice
for the remainder of the study. Mice on the 60→ 10% diet weighed
significantly less compared to mice on 60% diet at week 11 until
the end of study (P = 0.01) (Figure 2A).
Mice in the 60 and 60→ 10% groups gained body fat from 3 to
10 weeks of age while on the 60% obesogenic diet, and had signifi-
cantly greater body fat composition compared to the 10%-fed mice
at 10 weeks of age (P = 0.0008, 60→ 10 vs. 10%, and P < 0.05, 60
vs. 10%, Figure 2B). At 12 weeks of age, 2 weeks after diet switch
at 10 weeks, body fat content in the 60→ 10% mice decreased
significantly to levels detected in 10%-fed mice and remained low
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FIGURE 2 | Diet crossover induced loss of weight and fat mass
compared to obese C3(1)-TAg mice. (A) C3(1)-TAg mice were weighed
weekly at start of diets at weaning (3 weeks of age) (*P =0.001 from
weeks 9 to end of study vs. 60%; ∧P =0.01 from weeks 11 till sacrifice vs.
60%). (B) Body composition was measured by MRI at indicated weeks.
Diet switch from 60% to control 10% diet is indicated with arrow in (A,B).
(*P <0.05 vs. both 60 and 60→10%; ∧P <0.05 vs. 60%). n=15 in each
diet group.
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FIGURE 3 | Weight loss reduced obesity-induced tumor
progression but did not change latency. (A) Tumor progression
measured as percent change in volume from latency to sacrifice
3 weeks later (* vs. 10% P =0.001 and vs. 60→10% P =0.0024).
n=15 in each diet group. (B) Tumor cell size was measured over five
distinct fields of analyses/tumor section [* 10% (P =0.043) and 60%
(P =0.019) vs. 60→ 10%]. n=30 cells from five fields (total n= 150
cells) from five mice in each diet group. (C) Latency of first tumor
identified (DF, degrees of freedom). (D) Total tumor burden was
assessed at sacrifice. n=15 in each diet group.
until sacrifice. Mice fed the 60% diet exhibited greater body fat
compared to 10 and 60→ 10%-fed mice from weeks 12 until sac-
rifice (P < 0.05 at weeks 12 and 14, and at sacrifice; Figure 2B).
There were no significant declines in absolute lean mass in grams
in any of the diet groups tested (data not shown).
OBESITY INCREASED C3(1)-TAG TUMOR PROGRESSION, WHICH COULD
BE REVERSED BY WEIGHT LOSS
Tumor progression, as defined by percent change (increase) in
tumor volume from time of detection over 3 weeks until sacrifice,
as defined in methods, was significantly elevated in obese mice
compared to lean controls (P = 0.001, Figure 3A). In 60→ 10%-
fed mice, tumor progression was significantly inhibited compared
to obese 60%-fed mice (P = 0.002, Figure 3A). Tumor progres-
sion in 60→ 10%-fed mice was identical to lean 10%-fed mice.
Tumor progression for every tumor detected prior to sacrifice
was also calculated and was identical to primary tumor (data
not shown). Average tumor sizes at tumor onset (first tumor
detected; latency) were identical: 22.53± 9.27, 22.74± 10.06, and
23.25± 9.05 mm3 (P = 0.18) in mice fed 10, 60, and 60→ 10%,
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FIGURE 4 | Obesity-elevated measures of insulin resistance and
adiposity were reduced by weight loss. (A) 6 h fasted blood glucose was
measured in weanlings pre-diet, at 10 weeks of age at diet crossover, and at
sacrifice 3 weeks after tumor identification [* 10% (P =0.013) and
60→10% (P =0.0012) vs. 60%]. (B) Insulin was measured at sacrifice.
[* 10% (P =0.042) and 60→10% (P = 0.036) vs. 60%]. (C) HOMAIR
(glucose× insulin/405 was calculated from measures at sacrifice [* 10%
(P =0.028) and 60→10% (P =0.013) vs. 60%]. (D) Leptin [* 10%
(P =0.0157) and 60→10%-fed (P = 0.0155) vs. 60%] and (E) adiponectin
[* 10% (P =0.0301) and 60→10% (P = 0.0032) vs. 60%] were measured at
sacrifice. (F) Leptin: adiponectin ratios [* 10 and 60→10%-fed (P =0.005)
vs. 60%] were calculated from measures at sacrifice. n= 15 mice per diet
group for glucose measurements and n=14 for all other measures
including insulin, HOMAIR, leptin, adiponectin, and leptin:adiponectin ratios.
Table 1 | Systemic changes in inflammatory cytokines and
chemokines were not evident.
Cytokine/chemokine Diets
10% 60% 60→10%
IL-6 32.63±8.80 35.87±4.43 37.93±5.23
MCP-1 45.68±4.69 49.02±7.84 53.98±7.62
TNF-α 14.94±0.95 23.80±5.76 14.49±1.14
Plasma concentrations of IL-6, MCP-1, and TNF-α were measured at sacrifice for
n=15 mice per diet group.
respectively. In addition, there were no significant differences
in tumor cell sizes measured using Aperio Scanscope Toolbar
between mice on 10% diets compared to obese mice on 60%
diet. However, mice fed 60→ 10% diets exhibited significantly
smaller tumor cells compared with both 10% (P = 0.043) and
60% (P = 0.019) (Figure 3B). Mice on all three diets (10, 60,
and 60→ 10%) had similar latencies (Figure 3C). The hazard
ratios comparing 60–10% was 1.353 (95% CI of ratio: 0.63–2.9);
60→ 10–10% was 0.77 (95% CI of ratio: 0.36–1.6); and 60→ 10–
60% was 0.60 (95% CI of ratio: 0.27–1.3). Mean latency in 10,
60, and 60→ 10%-fed mice was 16.15, 16.26, and 15.82 weeks,
respectively. Using chi-square tests with a degree of freedom
of 2, 10 vs. 60% equaled 0.60, 10 vs. 60→ 10% equaled 0.47,
and 60 vs. 60→ 10% was 1.64. Tumor burden (total number of
tumors) was not significantly altered by obesity or weight loss
(Figure 3D).
OBESITY-INDUCED INSULIN RESISTANCE AND ADIPOSITY WERE
REVERSIBLE BY DIET INTERVENTION
We examined metabolic parameters that can contribute to obesity-
induced carcinogenesis (24). Glucose levels at diet start and at
diet switch were not different among any of the three groups
(Figure 4A). At sacrifice, 60%-fed obese mice had significantly
elevated blood glucose compared to the 10 and 60→ 10%-fed
mice (P = 0.01 and P = 0.001, respectively Figure 4A). Obese
mice had a 2.6-fold (P = 0.04) and a 2.5-fold (P = 0.03) ele-
vated plasma insulin levels compared to 10 and 60→ 10%-fed
animals, respectively (Figure 4B). HOMAIR score, calculated as
a marker of glucose intolerance, indicated that 60%-fed mice
were insulin resistant compared to 10%-fed mice (P = 0.03). Diet
switch-induced weight loss significantly blunted insulin resistance
(P = 0.01) compared to 60%-fed mice and the levels were identical
to 10%-fed mice (Figure 4C).
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FIGURE 5 | HGF is elevated by obesity and reduced by weight loss.
(A,B) Representative IHC photomicrographs (40×) and HGF quantified
in normal mammary gland [* 10% (P = 0.0102) and 60→10%
(P =0.0031) vs. 60%]. (C,D) Representative 40× photomicrographs
and HGF quantifications in tumor. Staining was quantified in normal
mammary glands and tumors in n=2 sections from eight mice using
Aperio Imagescope software and the color deconvolution algorithm
measuring positive pixel counts for diaminobenzidine (DAB) staining.
Aperio digital analysis of DAB allows for no subjective bias in
quantification.
Leptin and adiponectin are two important adipokines asso-
ciated with breast cancer (24). Leptin concentrations were sig-
nificantly greater in 60%-fed mice compared to 10% (P = 0.02,
Figure 4D). Mice on 60% diet exhibited significantly lower
adiponectin levels compared to 10% (P = 0.03, Figure 4E). In
60→ 10%-fed mice, leptin was dramatically reduced compared
to obese mice (P = 0.02, Figure 4D) mice. Likewise, adiponectin
was elevated in 60→ 10%-fed mice compared to 60%-fed mice
(Figure 4E, P = 0.003). There were no significant differences
between 10 and 60→ 10%-fed mice in leptin or adiponectin con-
centrations. The leptin:adiponectin ratio is an important indicator
of cancer risk (24). Leptin:adiponectin ratios of 60%-fed mice were
significantly elevated compared to 10 and 60→ 10%-fed mice
(P = 0.005; Figure 4F). Plasma levels of cytokines and chemokines
associated with obesity were measured (24). No significant differ-
ences were observed in plasma concentrations of IL-6, MCP-1, or
TNF-α among diet groups (Table 1).
HGF/C-MET CONCENTRATIONS IN NORMAL MAMMARY GLANDS AND
TUMORS WERE INDUCED BY OBESITY AND REDUCED WITH WEIGHT
LOSS
Obesity in 60%-fed mice significantly elevated HGF concentra-
tions in the normal mammary gland (Figures 5A,B) compared to
mice fed 10% diet (P = 0.01). Weight loss by 60→ 10% diet switch
significantly reduced the HGF expression (P = 0.003) compared
to mice fed 60% diet. HGF detected in 60→ 10%-fed mammary
glands were similar to concentrations in the control 10%-fed mice
(Figures 5A,B). In tumors, HGF protein concentrations were not
significantly regulated by obesity or weight loss (Figures 5C,D).
Similarly, c-Met protein concentrations in the normal mam-
mary gland were significantly elevated in the obese 60%-fed
mice compared to 10%-fed controls (P = 0.04, Figures 6A,B). c-
Met concentrations were significantly decreased by weight loss in
the 60→ 10%-fed group compared to the obese 60%-fed mice
(P = 0.004) and were similar to concentrations in the control
10%-fed mice (Figure 6B). In tumors, c-Met protein concentra-
tions were also significantly elevated in the 60%-fed mice com-
pared to the 10%-fed mice (P = 0.04, Figures 6C,D). Weight loss
60→ 10%-fed mice exhibited a significant decrease in c-Met pro-
tein concentrations compared to 60%-fed mice (P = 0.02). c-Met
concentrations in 60→ 10%-fed mice were similar to levels in the
lean 10%-fed mice.
HGF-ACTIVATED ITS DOWNSTREAM SIGNAL PI3K/Akt, BUT NOT
P70S6K
On HGF binding, c-Met undergoes dimerization and autophos-
phorylation leading to the activation of downstream phos-
phatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) and p70
Frontiers in Oncology | Molecular and Cellular Oncology July 2014 | Volume 4 | Article 175 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sundaram et al. Weight loss inhibits obesity-driven BBC
n
o
rm
a
l 
m
a
m
m
a
ry
A B
C
D
tu
m
o
rs
10% 60% 60 → 10%
0
5
10
15
20
*
Diets
%
 c
-M
E
T
+
 s
ta
in
in
g
 i
n
N
o
rm
a
l 
m
a
m
m
a
ry
 g
la
n
d
10% 60% 60 → 10%
0
2
4
6
8 *
Diets
%
 c
-M
E
T
+
 s
ta
in
in
g
 i
n
 t
u
m
o
r
10%
60% 60à10%
10%
60% 60à10%
No primary
No primary
FIGURE 6 | c-Met is elevated by obesity and reduced by weight loss.
(A,B) Representative IHC photomicrographs (40×) and c-Met quantified in
normal mammary [* 10% (P =0.036) and 60→10% (P =0.004) vs. 60%].
(C,D) Representative photomicrographs (40×) and tumor quantifications
[* 10% (P =0.043) and 60→10% (P =0.019) vs. 60%]. Staining was
quantified in normal mammary glands and tumors in n=2 sections from five
mice using Aperio Imagescope software and the membrane IHC algorithm for
c-Met quantification.
S6K signaling pathways which mediate effects of HGF including
cell survival, invasion, and metastasis. We next examined HGF/c-
Met signaling by measuring PI3K/Akt and p70S6K activation.
Obesity significantly reduced pAkt concentrations in the normal
mammary gland (Figures 7A,B) compared to mice fed 10% diet
(P = 0.039). Weight loss by 60→ 10% diet switch significantly
elevated the pAkt expression (P = 0.001) compared to mice fed
60% diet. Phospho-AKT concentrations in 60%-fed normal mam-
mary glands were similar to concentrations in the control 10%-fed
mice. In tumors, pAkt protein concentrations were significantly
elevated by the 60→ 10% diet switch compared to mice fed 10%
(P = 0.001) and 60% (P = 0.002) diets (Figures 7C,D). Phospho-
S6 levels in both normal mammary glands and tumors remained
unaltered by obesity or weight loss (Figures 8A–D).
DISCUSSION
Increases in adiposity, regardless of age, increase the risk of breast
cancer (4, 5, 31–35). It has been suggested that a significant burden
of BBC could be prevented by reducing obesity (4). Studies have
previously reported in humans that weight loss or prevention of
weight gain is protective against both pre- and post-menopausal
breast cancer. Weight loss in adulthood is associated with a reduced
risk of developing breast cancer compared to adult weight gain
(36–39). Furthermore, women who maintained weight loss of
more than 5 kg for at least 4 years after age 18 were shown to
be at decreased risk of developing pre-menopausal breast cancer
(40), while prevention of weight gain between age 18 years and
menopause, or weight loss and maintenance of loss during these
years, reduced the risk of post-menopausal breast cancer (37).
Coates et al. demonstrated a statistically significant 36% reduction
in risk when weight loss was achieved with respect to low-grade
tumors only in pre-menopausal women (41). However, contrast-
ing reports from three studies have shown that weight loss over
a prolonged interval did not significantly reduce risk of develop-
ing breast cancer (42–44). The Women’s Health Initiative (WHI)
Randomized Controlled Dietary Modification Trial in post-
menopausal women indicated that a dietary intervention group
exhibited 9% non-significant lower risk compared to the control
group after 8 years of follow-up (45). These studies suggest that
weight loss is likely beneficial in reducing risk. However, in human
populations, weight loss is due to heterogeneous causes, hence, it is
unclear whether dietary interventions are warranted and whether
these interventions would specifically reduce BBC (27).
Studies in pre-clinical mouse models have demonstrated that
diet-induced obesity is associated with shortened mammary
tumor latency of mainly luminal subtype (9, 10). In BBC C3(1)-
TAg GEMMs, our previous studies reported increased tumor
aggressiveness as measured by significantly shortened tumor
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FIGURE 7 | pAkt is reduced by obesity and elevated by weight loss.
(A,B) Representative IHC photomicrographs (40×) and pAkt quantified in
normal mammary [* 10% (P =0.039) and 60→10% (P =0.001) vs. 60%].
(C,D) Representative photomicrographs (40×) and tumor quantifications
[* 10% (P =0.001) and 60% (P =0.002) vs. 60→10%]. Staining was quanti-
fied in normal mammary glands and tumors in n=2 sections from five mice
using Aperio Imagescope software and the color deconvolution algorithm
measuring positive pixel counts for diaminobenzidine (DAB) staining.
latencies after mice were made obese by high-fat diet exposure
in adulthood (24). Herein, to examine if obesity-associated risk of
BBC was reversible, we modeled weight loss in adulthood following
life-long diet-induced obesity from weaning. Our data demon-
strated that weight loss and reduction in adiposity by diet switch to
a low-fat diet was achievable within a short period of time. While in
our previous study, we detected obesity-shortened latency, herein
when mice were exposed to diets from weaning into adulthood,
there were no significant diet-induced alterations on latency or
tumor burden. This demonstrates the importance of timing of
administration of diet and suggests that early diet exposure in this
GEMM does not alter early tumor growth (latency) since tumors
were the same size when detected. However, weight loss signifi-
cantly and dramatically reduced obesity-driven tumor progression
to growth levels detected in lean mice. Hursting et al. have also
shown that dietary energy interventions through caloric restric-
tion suppressed progression of basal-like xenografts compared to
lean control-fed mice (46). Modification of tumor growth could
have occurred through changes in tumor cell size. No significant
changes in cell size were detected between lean and obese, how-
ever weight loss exhibited significant decreases in tumor cell size
compared to the other groups. However, when pathways known to
be regulated by obesity that regulate tumor growth or tumor cell
size were examined, it was evident that pAKT was regulated in the
reverse manner (i.e., reduced with obesity in normal mammary).
In tumors, pAkt concentrations were significantly increased with
weight loss compared to both lean and obese mice. Phospho-AKT
is the target of many pathways including insulin, thus activation of
pAKT may be a measure of insulin sensitivity, which was reversed
with weight loss to control levels. mTOR/pS6 was not regulated
by obesity or weight loss in normal mammary or tumors. Thus,
it was not likely that pAKT or mTOR were dramatic regulators of
obesity or weight loss-mediated tumor growth in this model.
The effects of obesity on the mammary gland may depend upon
the timing of exposure. Animal studies have shown that high-fat
diet or obesity alters puberty onset (47,48),mammary gland devel-
opment and morphology (49–51), and tumor latency (9). Pubertal
alterations including inflammatory cell composition, increased
local production of growth factors, and angiogenesis may also
contribute to the promotion of mammary carcinoma (52). Distin-
guishing between puberty and adulthood obesity-associated risks
is important because both have distinct effects on stromal remod-
eling, and stromal-epithelial interactions modulate breast cancer
behavior in vivo (24). During puberty, the stroma is remodeled
as the gland develops to a mature, functional mammary gland
(53). Once maturity is reached, changes to the stroma are less dra-
matic,but recent data have suggested that obesity affects mammary
stroma (14, 54–57). Ongoing studies are currently investigating the
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FIGURE 8 | pS6 is not modulated by obesity or weight loss.
Representative IHC photomicrographs (40×) and pS6 quantified in normal
mammary (A,B) and tumors (C,D). Staining was quantified in normal
mammary glands and tumors in n= 2 sections from five mice using Aperio
Imagescope software and the color deconvolution algorithm measuring
positive pixel counts for diaminobenzidine (DAB) staining.
effects of obesity and weight loss in pubertal versus adult windows
of susceptibility to aid in clarifying when risk is most strongly
associated with BBC.
Systemic or microenvironmental alterations may have con-
tributed to tumor progression in C3(1)-TAg GEMMs. We mea-
sured metabolically regulated potential mediators such as glucose,
insulin, adipokines, and inflammatory proteins. Mice made obese
on the 60% diet displayed elevated glucose, insulin, HOMAIR
scores, and leptin and lower concentrations of adiponectin, which
together are characteristics of metabolic syndrome (22, 58).
Insulin is associated with greater risk of breast cancer (24, 59). In
the WHI study, fasting insulin concentrations in the highest quar-
tile were associated with 2.4-fold increase in BC risk compared to
women in the lowest quartile (24). The leptin:adiponectin ratio is
also an important indicator of cancer risk (24, 60). We observed
increased leptin:adiponectin ratios in the obese group, which were
reversed by weight loss to levels detected in lean mice. Increased
obesity has been shown to correlate with increased inflamma-
tion, including inflammatory cytokines such as TNF-α, IL-6, and
MCP-1 (59). However, no significant obesity- or weight-loss medi-
ated differences in plasma levels of cytokines and chemokines
were detected, suggesting that pro-inflammatory mediators likely
did not contribute to tumor progression in C3(1)-TAg mice in
this experimental design. Taken together, reduction in meta-
bolically regulated hormones and adipokines, but not systemic
inflammatory mediators, may have contributed to reduced tumor
progression after weight loss in C3(1)-TAg mice.
Microenvironmental alterations in the normal mammary are
important in BBC (61, 62). The mammary gland is similar to other
adipose depots in that obesity drives stromal alterations such as
elevations in immune cells or growth factors that are established
contributors to breast cancer risk (14, 22, 57, 63–65). The HGF/c-
Met axis is one such pathway linked to both obesity and breast
cancer risk that previously had not been investigated in tandem.
The HGF/c-Met signature is highly expressed in almost 90% of
basal-like cancers from patients (15). HGF is elevated in obese
adipose tissue, and high concentrations of serum HGF detected
in obese individuals may be blunted by weight loss (20, 66). Fur-
thermore, we previously reported elevated HGF protein concen-
trations in normal mammary of obese C3(1)-TAg mice compared
to lean mice (14). Using ex vivo coculture models, we reported
that proliferation and motility were specifically induced by HGF,
by using blocking antibodies (14, 16). These studies suggested that
HGF’s effects on proliferation and motility are likely involved in
tumor progression (14, 16). Here, we report that switching C3(1)-
Tag mice from obesogenic to a low-fat diet reversed HGF and
c-Met expression in normal mammary glands to levels detected
in lean controls. Although HGF protein concentrations in tumors
were not significantly modified by obesity, similar to our previous
findings (14), c-Met was dramatically elevated with obesity, and
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significantly blunted to control levels by weight loss. These data
suggest that alterations to the HGF/c-Met pathway that occur in
the normal mammary gland and tumor set the stage for tumor
progression. Future studies to elucidate the efficacy of inhibiting
this pathway using novel small molecule therapeutics to miti-
gate obesity-driven BBC need to be undertaken. Taken together,
our data demonstrate that obesity increased tumor progression,
which was reversed by weight loss, likely by reducing important
obesity-associated metabolic and growth factors.
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